FDA grants LENVIMA and KEYTRUDA combination therapies for the treatment of hepatocellular cancer patients
-
Last Update: 2020-06-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, Aisho and Mershadon announced that the U.SFoodmedicine(http://Regulatory Authority (
FDA(http://) has awarded LENVIMA (Chinese product name "LeWeima") and KEYTRUDA (Chinese commodity name "Corida") combination therapy "breakthrough therapy" as a potential first-line treatment for patients with advanced non-reprectoable hepatocellular (HCC) who cannot be treated locallyLeWeima is an oral protein kinase inhibitor developed by WeishiCorida is an anti-PD-1 therapy developed by Mercadothis is the third "breakthrough therapy" awarded to the combination therapy of LeWei-Ma-Corridathe first two "breakthrough therapies" awarded by this combination therapy were: january 2018 for patients with advanced and/or metastatic renal cell carcinoma, and July 2018 for patients with advanced or metastatic non-high lyator microsatellite instability (MSI-H)/misalignment repair function normal (pMMR) patientsThis "breakthrough therapy" designation is based on the latest interim results of the 1bTrial(http://KEYNOTE-524/116the results of the study, which was presented at the 2019 annual meeting of the American Association for Cancer Research (AACR), were the mid-termanalysis of theof theanalysis(http://The effectiveness and safety of this combination therapy are still in trial, and their effectiveness and safety have not yet been approved for the treatment of any type of cancer
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
